Q2 Earnings Forecast for Repligen Issued By Leerink Partnrs

Repligen Co. (NASDAQ:RGEN - Free Report) - Analysts at Leerink Partnrs reduced their Q2 2025 earnings per share estimates for Repligen in a report released on Thursday, April 17th. Leerink Partnrs analyst P. Souda now expects that the biotechnology company will post earnings per share of $0.42 for the quarter, down from their previous estimate of $0.43. The consensus estimate for Repligen's current full-year earnings is $1.72 per share. Leerink Partnrs also issued estimates for Repligen's Q4 2025 earnings at $0.50 EPS, FY2025 earnings at $1.70 EPS and FY2026 earnings at $2.29 EPS.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million during the quarter, compared to analysts' expectations of $167.58 million.

RGEN has been the topic of a number of other research reports. Royal Bank of Canada raised their target price on shares of Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research note on Friday, February 21st. TD Cowen started coverage on shares of Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 target price on the stock. StockNews.com downgraded Repligen from a "hold" rating to a "sell" rating in a research report on Thursday. Canaccord Genuity Group dropped their price objective on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. Finally, HC Wainwright reissued a "buy" rating and set a $180.00 target price on shares of Repligen in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Repligen presently has a consensus rating of "Hold" and a consensus target price of $176.82.

Repligen Stock Performance

NASDAQ:RGEN traded up $1.64 during mid-day trading on Friday, hitting $131.64. 678,928 shares of the company traded hands, compared to its average volume of 708,183. The stock's fifty day moving average price is $140.37 and its 200-day moving average price is $145.78. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a one year low of $102.97 and a one year high of $182.52. The firm has a market cap of $7.39 billion, a price-to-earnings ratio of -258.12, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27.

Insider Activity

In other news, Director Margaret Pax acquired 250 shares of the firm's stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.20% of the company's stock.

Institutional Trading of Repligen

A number of hedge funds and other institutional investors have recently bought and sold shares of RGEN. Stifel Financial Corp grew its stake in Repligen by 5.4% in the third quarter. Stifel Financial Corp now owns 4,404 shares of the biotechnology company's stock worth $655,000 after purchasing an additional 226 shares in the last quarter. MML Investors Services LLC boosted its stake in Repligen by 2.7% in the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company's stock valued at $503,000 after acquiring an additional 89 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of Repligen in the 3rd quarter worth $233,000. Tidal Investments LLC increased its holdings in shares of Repligen by 142.8% during the third quarter. Tidal Investments LLC now owns 11,149 shares of the biotechnology company's stock valued at $1,659,000 after acquiring an additional 6,558 shares in the last quarter. Finally, Peapack Gladstone Financial Corp purchased a new position in shares of Repligen in the third quarter worth $296,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.